Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient

Introduction Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. Case report We report the case of a patient who developed unusu...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of oncology pharmacy practice Vol. 28; no. 4; pp. 995 - 997
Main Authors:	Nefzi, Issad, Yahyaoui, Yosra, Letaief, Feriel, Ghammem, Nour, Gabsi, Azza, Ayadi, Mouna, Mezlini, Amel
Format:	Journal Article
Language:	English
Published:	London, England SAGE Publications 01-06-2022 Sage Publications Ltd
Subjects:	Biopsy Chemotherapy Colony-stimulating factor Erythema Erythema nodosum Ewing's sarcoma Ewings sarcoma Filgrastim - therapeutic use Granulocyte Colony-Stimulating Factor Humans Lenograstim Lesions Leukocytes (granulocytic) Nausea Neutropenia Patients Pustulosis Pyoderma Pyoderma gangrenosum Recombinant Proteins - adverse effects Sarcoma, Ewing - drug therapy Skin Diseases - chemically induced Sweet's syndrome Toxicity Filgrastim skin toxicity toxidermy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. Case report We report the case of a patient who developed unusual, non-commonly reported adverse toxidermy to filgrastim. At first the eruption was limited to the lower members and genetics organs. Then it slowly spread across the whole body presenting as a polymorphic exanthematous-pustulosis lesions. Management & Outcome A cutaneous biopsy was done, identifying a toxidermy modified by systemic treatment. A pharmacological study linked the role of filgrastim to these lesions. After switching from filgrastim to lénograstim, his lesions are completely gone and haven't flared up again. Thus, clearly imputing the use of filgrastim. Discussion The cutaneous reaction that has reported with use of GSCF are sweet syndrome, erythema nodosum, pyoderma nodosum and pyoderma gangrenosum. As far as we know, no acute generalized exanthematous pustulosis due to GSCF has been reported.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1078-1552 1477-092X
DOI:	10.1177/10781552211073802